中国药科大学:调节肠道菌群或有助于降血脂
创作:梁婷 审核:szx 2018年10月09日
  • 选取21项随机对照临床试验(1436名受试者),对用于调节肠道菌群的产品(包括益生菌、益生元、合生制剂等)对高脂血症的影响进行荟萃分析;
  • 与安慰剂相比,用于调节肠道菌群的产品对血清总胆固醇、LDL/HDL胆固醇的浓度有显著影响,而对甘油三酯浓度无显著性影响;
  • 亚组分析显示,益生菌和长期干预对降低血脂水平有更好的效果;
  • 用于调节肠道菌群的产品的持久性、安全性和副作用尚未确定,应进一步结合降脂药物的作用进行相关研究。
主编推荐语
szx
来自中国药科大学在European Journal of Nutrition上发表的一项最新荟萃分析,选取了21项随机对照临床试验(近1500名受试者),发现益生菌等可调节肠道菌群的产品有助于改善高血脂,但其持久性、安全性还需进一步研究。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Effects of products designed to modulate the gut microbiota on hyperlipidaemia

用于调节肠道菌群的产品对高脂血症的影响

10.1007/s00394-018-1821-z

2018-09-20, Article

Abstract & Authors:展开

Abstract:收起
Purpose: Fatalities due to heart and cerebrovascular diseases caused by uncontrolled hyperlipidaemia increase every year; on the other hand, lipid-lowering drugs are known to cause side effects. The gut microbiota has been thoroughly investigated by researchers and consumers, because they have unique functional properties and littler side effects. However, the effects of the gut microbiota remain controversial. We conducted a meta-analysis to assess the effects of products designed to modulate the gut microbiota on various hyperlipidaemias.
Methods: We systematically searched PubMed, Embase, Cochrane Library (Central), and Web of Science for randomized controlled trials (published before June 2017, and those only in English) to compare treatment (products designed to modulate the gut microbiota) versus placebo. Our main endpoints were total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in serum. We assessed pooled data using a fixed effects model.
Results: Of 1337 identified studies, 21 were eligible and included in our analysis (n = 1436 participants). The combined estimate of effect size for the impact of products designed to modulate the gut microbiota on serum TC (WMD − 11.07 mg/dL, 95% CI − 13.72 to − 8.43, p < 0.001), LDL-C (WMD − 10.96 mg/dL, 95% CI − 13.37 to − 8.56, p < 0.001), and HDL-C (WMD 0.72 mg/dL, 95% CI 0.06–1.38, p = 0.032) were statistically significant, while no significant effect was found on TG concentrations (WMD − 0.56 mg/dL, 95% CI − 5.59 to 4.47, p = 0.828). Subgroup analysis showed parallel trials, probiotics, and long-term intervention had better effects on lowering blood lipid levels.
Conclusion: Products designed to modulate the gut microbiota results in changes of the plasma lipid concentrations and these changes may protect against cardiovascular disease.

First Authors:
Xilong Deng

Correspondence Authors:
Weihong Ge,Changrun Guo

All Authors:
Xilong Deng,Jie Ma,Meiting Song,Ye Jin,Cheng Ji,Weihong Ge,Changrun Guo

评论